Table 13– Results from the European Lung Cancer Audit prospective data collection study: May 2012 data

Country	Patients n	Expected new patients^#	Males	Age years	Histology					PS		Stage					NSCLC + surgery	SCLC + CTx
					Adeno	SCC	NOS	OS	SCLC	0–1	4	I	II	III	IV	Missing
Albania	15	15	80	62 (48–65)	13	47	20	14	7	66	0	0	33	47	13	7	71	100
Austria	61	18	66	69 (64–72)	46	31	2	12	10	84	0	28	2	28	39	3	38	83
Belgium	7	0	86	70 (52–80)	86	14				71	0	29	43	29	0	0	71
Bulgaria	197	59	83	65 (59–72)	23	38	22	4	13	46	8	4	8	35	50	4	6	76
Croatia	90	37	80	68 (60–75)	43	36	2	8	11	82	4	3	2	23	47	24	11	70
Czech	81	15	70	66 (61–72)	21	47	7	6	19	70	0	5	1	36	51	7	9	93
Estonia	51	80	75	64 (59–72)	29	35	4	10	22	73	2	18	12	33	31	6	38	82
Germany	79	2	72	68 (62–75)	49	32	4	6	9	65	3	10	13	30	43	4	32	100
Greece	23	4	91	63 (58–70)	26	22	17	4	30	74	0	0	4	26	43	26	6	86
Ireland	70	42	46	70 (62–76)	33	34	9	3	21	79	0	33	14	20	20	13	53	87
Latvia	57	65	86	71 (62–75)	40	26	7	9	18	63	4	17	11	32	39	2	26	70
Lithuania	26	21	77	64 (57–74)	23	50	4	4	19	81	0	4	4	23	38	31	43	100
Luxembourg	6	27	66	65 (61–75)	50	50				83	0	33	17	0	50	0	50
Norway	35	16	46	67 (62–74)	26	29	26	14	6	69	0	23	0	40	37	0	21	100
Poland	142	7	68	66 (59–73)	20	37	13	8	23	68	1	10	9	33	42	6	25	76
Portugal	77	28	79	64 (55–73)	51	27	5	4	13	83	1	9	4	30	51	6	21	90
Serbia	283	54	78	63 (57–68)	38	37	2	5	18	81	1	5	6	31	46	11	26	88
Slovakia	4	2	50	56 (50–63)	25	25	25		25	50	0	0	0	50	50	0	0	100
Slovenia	38	37	58	64 (54–72)	53	18	5		24	76	5	16	8	21	53	3	17	89
Spain	255	13	82	67 (58–75)	38	31	5	12	14	71	3	16	8	26	45	5	28	92
Switzerland	13	4	69	71 (61–72)	38	31	23	7		77	0	31	7	31	31	0	46
Turkey	391	32	88	62 (56–59)	24	38	16	8	14	65	3	10	8	30	40	12	28	91
Ukraine	28	2	93	63 (57–67)	14	39	39	8		93	4	25	7	29	39	0	43
Denmark^¶	172	49	56	71 (64–78)	35⁺	19	17	14	15	62	4	20	23	13	37	6	17	81
England^¶	656	26	54	Mean 72	19	15	11	8	11	32	6	7	6	21	43	22	14	81
Wales^¶	116	68	57	69 (61–76)	32	29	15	5	19	63	1	11	8	25	52	4	16	73

Data are presented as % or median (interquartile range), unless otherwise stated. Bold indicates <30 new patients entered into European Lung Cancer Audit study. Adeno: adenocarcinoma. SCC: squamous cell carcinoma; NOS: nonsmall cell lung cancer (NSCLC) not otherwise specified; OS: other specific NSCLC; SCLC: small cell lung cancer; PS: performance stage; CTx: chemotherapy. ^#: data are from GLOBOCAN, except for data from England and Wales that are from NLCA; ^¶: data from established audit programme; ⁺: histology and treatment data are based on 2011 data.